Is compounded semaglutide the same as Ozempic?

Was compounded semaglutide ever legal, and is that still true today?

It was legal under a specific, temporary legal basis that has since expired. Pharmacy compounding law permits compounders to produce a version of a drug that is in shortage, under conditions set out in sections 503A and 503B of the FD&C Act. FDA determined that the shortage of semaglutide injection products was resolved as of 21 February 2025 [2].

Once a shortage ends, FDA's enforcement discretion allowing compounding does not end immediately; the agency provided a wind-down period, and for semaglutide specifically, that discretion ended 22 April 2025 for state-licensed 503A pharmacies and 22 May 2025 for 503B outsourcing facilities [2]. FDA's own framing is direct: compounded products that are essentially a copy of an approved drug face legal restrictions once that drug is no longer in shortage [2]. As of September 2026, both deadlines are well past, meaning the shortage-based legal basis that once existed for compounding semaglutide broadly no longer applies.

Does 'semaglutide' in a compounded product mean the same active ingredient as in Ozempic?

Not necessarily, and this is a chemistry question separate from the legal-basis question above. FDA states plainly that certain compounded product variants use semaglutide sodium and semaglutide acetate, and that these salt forms are different active ingredients than those used in the approved drugs [3].

A salt form changes the chemical composition of what is actually administered, even when the base molecule is related, and FDA's own concerns page notes the agency lacks data confirming these salt forms behave the same pharmacologically as the approved product's active ingredient [3]. A product labelled semaglutide is therefore not a guarantee that its active ingredient is chemically identical to what is inside an Ozempic pen; the label name and the actual molecule present can diverge, independent of any question about the compounding pharmacy's competence or good faith.

What documented safety problems has FDA tied specifically to compounded semaglutide?

FDA's July 2024 alert describes documented, real-world harm distinct from any question about ingredient sourcing or purity. The agency identified that unfamiliarity with withdrawing medication from a vial into a syringe, coupled with confusion between units of measurement, may have contributed to dosing errors [4].

This arose specifically because compounders offered multiple different concentrations simultaneously, patients often received syringes larger than needed for their prescribed volumes, and dosing instructions sometimes used units as a measurement term where patients expected milligrams or millilitres [4]. This is a packaging-and-presentation risk that exists independently of whether a given compounded batch was, in fact, chemically pure and correctly labelled; even a well-manufactured compounded product carries this risk if its concentration and instructions differ from what a patient is used to handling with the approved pen.

What happens when a seller markets semaglutide products outside both the approval framework and the now-expired shortage exception?

FDA treats this as ordinary unapproved-drug marketing, and 2026 enforcement activity shows this is not a theoretical scenario. FDA's warning letter to an online peptide seller names semaglutide among products cited as unapproved new drugs, despite the company's research use only and not for human consumption labelling [6].

FDA's broader concerns page adds that compounded drugs are not FDA approved and undergo no agency review for safety, effectiveness or quality before they are marketed, and separately warns of improper storage during shipping that compromises drug integrity, and contamination risks in multi-dose vials beyond 28 days of use [5]. The agency has also established an import alert specifically to prevent GLP-1 active pharmaceutical ingredients with quality concerns from entering the US supply chain, and has warned about outright counterfeit products using false pharmacy names [5]. None of this enforcement activity depends on whether the shortage-based compounding exception is still active; it applies to products marketed as unapproved drugs regardless of that separate legal question.

What does independent testing show about semaglutide products from unregulated online sources?

A 2024 peer-reviewed study gives a concrete picture of what unregulated can mean in practice for this specific molecule. Researchers purchasing semaglutide from online sellers outside the prescription and approved-pharmacy system found that all samples were assessed as probable substandard or falsified products, with content exceeding labelled amounts by 28.56 to 38.69 percent, purity between 7.7 and 14.37 percent against a 99 percent claim, and endotoxin detected in every sample [7].

This study examined products purchased through online sellers rather than through licensed 503A or 503B compounding pharmacies specifically, so it should be read as evidence about the broader unregulated online market for semaglutide-labelled products, not as a direct finding about every state-licensed compounding pharmacy's output.

What would change this answer

An FDA reversal reinstating shortage status for semaglutide, a published FDA or peer-reviewed comparison of licensed-compounding-pharmacy semaglutide against Ozempic's approved specifications, or a new FDA safety communication specifically addressing salt-form pharmacology data, which FDA currently states it lacks, would each change parts of this answer.